X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/30/2890689/0/en/Compass-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/28/2889425/0/en/Compass-Therapeutics-Announces-CEO-Transition.html
https://www.globenewswire.com/news-release/2024/05/23/2887702/0/en/Compass-Therapeutics-to-Present-Phase-1-Data-for-CTX-471-A-Novel-CD137-Agonist-Antibody-Demonstrating-Anti-Tumor-Activity-in-Patients-Who-Have-Progressed-on-Approved-PD-1-or-PD-L1-.html
https://www.globenewswire.com/news-release/2024/05/14/2881305/0/en/Compass-Therapeutics-to-Participate-in-the-H-C-Wainwright-2nd-Annual-BioConnect-Investor-Conference.html
https://www.globenewswire.com/news-release/2024/05/13/2880386/0/en/Compass-Therapeutics-Reports-2024-First-Quarter-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/04/25/2869573/0/en/Compass-Therapeutics-Receives-FDA-Fast-Track-Designation-for-the-Investigation-of-CTX-009-in-Combination-with-Paclitaxel-for-the-Treatment-of-Patients-with-Metastatic-or-Locally-Ad.html
https://www.globenewswire.com/news-release/2024/04/16/2863573/0/en/Compass-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-1-Study-of-CTX-8371-in-Patients-with-Solid-Tumors.html
https://www.globenewswire.com/news-release/2024/04/12/2862132/0/en/Compass-Therapeutics-Announces-Poster-Presentations-at-the-Cholangiocarcinoma-Foundation-2024-Annual-Conference.html
Market Place
Share 
